Person: İNANÇ, GÜZİDE NEVSUN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
İNANÇ
First Name
GÜZİDE NEVSUN
Name
3 results
Search Results
Now showing 1 - 3 of 3
Publication Open Access A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO registry(2022-04-01) İNANÇ, GÜZİDE NEVSUN; DİRESKENELİ, RAFİ HANER; Önen F., Can G., Çapar S., Dalkılıç E., Pehlivan Y., Şenel S., Akar S., Koca S. S., Tufan A., Yazıcı A., et al.Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018. Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treatments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens. Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a conventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31. Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in TurkeyPublication Open Access Pulmonary endarterectomy in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension(2022-05-01) KOCAKAYA, DERYA; ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; YILDIZELİ, BEDRETTİN; İNANÇ, GÜZİDE NEVSUN; Taş S., Antal A., Durusoy A. F., Yanartaş M., Yıldız K., Olgun Yıldızeli Ş., Kocakaya D., Mutlu B., Alibaz-Öner F., Direskeneli H., et al.Background: Antiphospholipid syndrome is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis. Chronic thromboembolism is one of the known established pathogenesis of pulmonary hypertension, known as chronic thromboembolic pulmonary hypertension. Pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension. The aim of this study is to evaluate the efficacy and risk of pulmonary endarterectomy in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension. Methods: Data were prospectively collected and retrospectively analyzed, for patients who underwent pulmonary endarterectomy between March 2011 and March 2020. Results: Seventeen patients (4 male and 13 female) were identified. Thirteen patients had primary antiphospholipid syndrome and 4 had secondary antiphospholipid syndrome. The mean age was 34.82 ± 10.07 years and the mean time interval between the diagnosis and surgery was 26.94 ± 17.35 months. Dyspnea on exertion was the main symptom in all patients. Seven patients had previous deep vein thrombosis, 5 patients had a history of recurrent abortions, and 2 patients had hemoptysis. Following surgery, mean pulmonary artery pressure decreased from 47.82 ± 13.11 mm Hg to 22.24 ± 4.56 mm Hg (P < .001), and pulmonary vascular resistance improved from 756.50 ± 393.91 dyn/s/cm−5 to 298.31 ± 132.84 dyn/s/cm−5 (P < .001). There was no in-hospital mortality with a mean follow-up of 75.29 ± 40.21 months. The functional capacity of all patients improved from 269.46 ± 111.7 m to 490 ± 105.34 m on a 6-minute walking test. Conclusions: Pulmonary endarterectomy is a safe and curative treatment in patients with antiphospholipid syndrome-associated chronic thromboembolic pulmonary hypertension. It has a favorable outcome by increasing the quality of life. A multidisciplinary experienced chronic thromboembolic pulmonary hypertension team is critical in the management of these unique patientsPublication Open Access Re: Risk of hbv reactivation in hbsag negative and antihbc igg positive patients receiving biologic therapy(2023-03-01) KANİ, HALUK TARIK; KARABACAK, MURAT; CÖMERT ÖZER, ELİF; ABACAR, KEREM YİĞİT; KUTLUĞ AĞAÇKIRAN, SEDA; SEVİK, GİZEM; ALİBAZ ÖNER, FATMA; İNANÇ, GÜZİDE NEVSUN; ATAGÜNDÜZ, MEHMET PAMİR; ÖZEN ALAHDAB, YEŞİM; DİRESKENELİ, RAFİ HANER; ATUĞ, ÖZLEN; Ergenç İ., KANİ H. T., KARABACAK M., CÖMERT ÖZER E., Mehdiyev S., Jafarov F., ABACAR K. Y., KUTLUĞ AĞAÇKIRAN S., SEVİK G., Aslan R., et al.